ZOMETA® Patient Case Study, Medical Profile and Diagnosis of a Renal Cell Carcinoma (RCC) Patient
ZOMETA - Zoledronic AcidZOMETA - Zoledronic Acid Novartis Oncology
HomeZOMETA - International SiteZOMETA - US ResidentsZOMETA - Country Sites
ZOMETA - English ZOMETA - Deutsch ZOMETA - Espanol ZOMETA - Francais ZOMETA - Italiano
ZOMETA-Videos
Blue Arrow View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
ZOMETA European Summary of Product Characteristics
Blue Arrow For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics
 
ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

Carlo V.
  • Aged 67 years
  • Retired accountant
  • Takes sculpting classes twice a week
Page  1 2 3

Diagnosis and treatment of bone metastases

  • Carlo presented last month with chest and lower back pain
  • Chest radiograph and CT scan revealed 2 metastatic lesions in the right thorax
  • MRI of the spine revealed metastases in the T10, T11, and T12 vertebrae
  • Immediately after his diagnosis, Carlo began treatment with daily sunitinib on a 6-week cycle(4 weeks on, 2 weeks off)






Page  1 2 3